A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug.

A class action lawsuit has been filed against CVS Caremark (NYSE:CVS), the pharmacy benefit manager for health insurer Aetna, after it dropped Eli Lilly's (NYSE:LLY) weight loss med Zepbound ...

“It is my professional opinion that the patient’s health problems all seem to be improving on Zepbound and we would be hesitant to switch medications when things are going well,” one of Cole’s doctors ...

Two New York residents have filed a lawsuit against CVS after the company’s pharmacy benefit manager, Caremark, denied coverage for Zepbound in favor of Wegovy. The plaintiffs — Dennis Larkin of ...

Pharmacy benefit manager CVS Caremark decided to replace Zepbound with Wegovy for use in weight loss starting July 1, despite Zepbound users having more weight loss success. The company will no longer ...

The healthcare sector is showing signs of recovery, and large insurers are drawing renewed attention from Wall Street.

A class-action lawsuit accuses CVS Caremark of denying medically necessary treatments by stopping coverage of Zepbound, Eli Lilly’s blockbuster weight-loss drug. CVS Caremark stopped covering Zepbound ...